Suscribirse

Correlation between Ficolin-3 and Vascular Endothelial Growth Factor-to-Pigment Epithelium-Derived Factor Ratio in the Vitreous of Eyes with Proliferative Diabetic Retinopathy - 21/11/11

Doi : 10.1016/j.ajo.2011.05.022 
Bingqing Zheng a, Tao Li a, Haibing Chen b, Xun Xu a, Zhi Zheng a,
a Department of Ophthalmology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, People's Republic of China 
b Shanghai Clinical Center for Diabetes Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China 

Inquiries to Zhi Zheng, Haining Road 100, Shanghai 200080, China

Resumen

Purpose

To investigate the relationship of ficolin-3 with inflammatory and angiogenic factors, namely, vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF), in the vitreous of eyes with proliferative diabetic retinopathy (PDR).

Design

Case-control study.

Methods

Vitreous fluid and serum samples were obtained at the time of vitreoretinal surgery from 21 eyes of 21 patients with PDR and from 16 eyes of 16 nondiabetic patients with idiopathic macular hole. Ficolin-3, VEGF, and PEDF concentrations were determined by enzyme-linked immunosorbent assay.

Results

Vitreous ficolin-3 levels were significantly higher in eyes with PDR than in eyes with idiopathic macular hole. Similarly, VEGF levels also were significantly higher in eyes with PDR than in eyes with idiopathic macular hole. In contrast, vitreous PEDF concentrations were significantly lower in eyes with PDR than in eyes with idiopathic macular hole, and the VEGF-to-PEDF ratio was higher in eyes with PDR than in eyes with idiopathic macular hole. Furthermore, a significant correlation between ficolin-3 and the VEGF-to-PEDF ratio was observed in the vitreous of eyes with PDR. In addition, serum ficolin-3 levels in eyes with PDR were higher than the levels in eyes with idiopathic macular hole, and the vitreous ficolin-3 levels also correlated with serum ficolin-3 levels.

Conclusions

We found that ficolin-3 levels were elevated in the vitreous fluid of patients with PDR. Our results suggest that ficolin-3 may be used as a new therapeutic target for treatment of PDR.

El texto completo de este artículo está disponible en PDF.

Esquema


Crown Copyright © 2011  Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 152 - N° 6

P. 1039-1043 - décembre 2011 Regresar al número
Artículo precedente Artículo precedente
  • Retinal and Choroidal Thickness in Early Age-Related Macular Degeneration
  • Ashley Wood, Alison Binns, Tom Margrain, Wolfgang Drexler, Boris Považay, Marieh Esmaeelpour, Nik Sheen
| Artículo siguiente Artículo siguiente
  • Identifying a Clinically Meaningful Threshold for Change in Uveitic Macular Edema Evaluated by Optical Coherence Tomography
  • Elizabeth A. Sugar, Douglas A. Jabs, Michael M. Altaweel, Sue Lightman, Nisha Acharya, Albert T. Vitale, Jennifer E. Thorne, Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.